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Abstract
Although coding variants in THAP1 have been causally associated with primary
dystonia, the contribution of noncoding variants remains uncertain. Herein, we
examine a previously identified Intron 1 variant (c.71+9C>A, rs200209986).
Among 1672 subjects with mainly adult-onset primary dystonia, 12 harbored the
variant in contrast to 1/1574 controls (P < 0.01). Dystonia classification included
cervical dystonia (N = 3), laryngeal dystonia (adductor subtype, N = 3), jaw-
opening oromandibular dystonia (N = 1), blepharospasm (N = 2), and unclassi-
fied (N = 3). Age of dystonia onset ranged from 25 to 69 years (mean = 54 years).
In comparison to controls with no identified THAP1 sequence variants, the
c.71+9C>A variant was associated with an elevated ratio of Isoform 1
(NM_018105) to Isoform 2 (NM_199003) in leukocytes. In silico and minigene
analyses indicated that c.71+9C>A alters THAP1 splicing. Lymphoblastoid cells
harboring the c.71+9C>A variant showed extensive apoptosis with relatively fewer
cells in the G2 phase of the cell cycle. Differentially expressed genes from lympho-
blastoid cells revealed that the c.71+9C>A variant exerts effects on DNA synthesis,
cell growth and proliferation, cell survival, and cytotoxicity. In aggregate, these data
indicate that THAP1 c.71+9C>A is a risk factor for adult-onset primary dystonia.
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Introduction
Dystonia is a neurological disorder characterized by
sustained or intermittent involuntary muscle contractions
leading to abnormal postures and movements that may
be tremulous (Fahn et al. 1998; Albanese et al. 2013).
Physiologically, dystonia may be associated with atypical
cocontractions of agonist and antagonist muscle groups,
impaired control of somatotopically contiguous muscles,
and reduced inhibition of spinal and brainstem reflexes
(LeDoux 2012a). Dystonia is classified along two axes:
clinical characteristics and etiological categories. Clinical
characteristics include age of onset, body distribution,
temporal pattern, coexistence of other movement disor-
ders, and other neurological manifestations (Fahn et al.
1998; LeDoux 2012b; Albanese et al. 2013). Etiological
categories include nervous system pathology and inher-
ited. In general, adult-onset dystonia without evidence of
overt degeneration or structural lesions of the nervous
system is referred to as primary or isolated dystonia and
inherited in autosomal-dominant fashion with reduced
penetrance (Fahn et al. 1998; LeDoux 2012b). To date,
coding mutations in TOR1A, THAP1, CIZ1, GNAL, and
ANO3 have been causally associated with primary dysto-
nia (Ozelius et al. 1997; Fuchs et al. 2009, 2012; Xiao,
et al., 2010; Xiao et al. 2012; Vemula et al. 2013). The
role of large structural and noncoding variants in the
etiopathogenesis of primary dystonia remains largely
unexplored (Moscovich et al. 2013).
Among the known genetic causes of adult-onset pri-
mary dystonia, THAP1 dystonia appears to be associated
with the most diverse ages of onset and anatomical distri-
butions (Fuchs et al. 2009; Xiao et al. 2010; LeDoux et al.
2012). THAP1 encodes Thanatos-associated THAP
domain containing, apoptosis-associated protein 1, encod-
ing DNA-binding transcription factor THAP1. Located on
Chr.8p11.21 (42,691,817–42,698,474: 6658 bp), the major
isoform of this gene (NM_018105) contains three exons.
THAP1 harbors a zinc-binding THAP domain, nuclear
localization signal, and coiled-coiled domain. This zinc-
binding domain is present in other proteins that are
involved in cell-cycle control, apoptosis, and transcrip-
tional regulation. THAP proteins are absent from plants
and bacteria, but found in Drosophila, Caenorhabditis ele-
gans, Xenopus, zebrafish, and mammals (Roussigne et al.
2003). Monomeric THAP1 shows low affinity for DNA
(Campagne et al. 2010), and amino acid residues 154–166
are critical for dimerization (Sengel et al. 2011). THAP1 is
widely expressed in brain and extraneural tissues including
whole blood (Zhao et al. 2013).
THAP1 binds to specific DNA sequences, regulating
cell proliferation and the G1/S checkpoint through
pRB/E2F cell-cycle target genes (Clouaire et al. 2005;
Cayrol et al. 2007; Sabogal et al. 2010; LeDoux et al.
2012, 2013). For instance, RRM1 is a direct transcrip-
tional target of THAP1 (Cayrol et al. 2007). Both overex-
pression and knockdown of THAP1 in endothelial cells
(ECs) inhibits proliferation.
To date, over 80 disease-specific sequence variants
have been localized to the coding regions of THAP1 and
associated with focal, segmental, multifocal, and general-
ized dystonia with age of onset ranging from 3 to over
60 years (LeDoux et al. 2012). Consistent with the char-
acteristically reduced penetrance of adult-onset dystonia,
several asymptomatic carriers have been identified in the
relatives of probands. The broad clinical heterogeneity of
THAP1 dystonia and low penetrance of known coding
variants suggest that noncoding variants in THAP1
could contribute to the risk of developing adult-onset
primary dystonia. In 2010, we identified a sequence vari-
ant (c.71+9C>A) (rs200209986) near the donor site
of Intron 1 that might increase the risk of developing
primary dystonia (Xiao, et al. 2010). The variant was
found in 7/1210 subjects with dystonia but only 1/600
controls. Although the control did not manifest dysto-
nia, she did report trismus and had experienced seizures
as a child. Herein, we present the results of a larger
definitive case–control study of THAP1 c.71+9C>A in
1672 subjects with primary, mainly adult-onset, dystonia
and 1574 neurologically normal Caucasian controls.
Moreover, we characterize the relative effects of THAP1
c.71+9C>A on cell-cycle control, splicing, and gene
expression.
Materials and Methods
Human subjects
All human studies were conducted in accordance with the
Declaration of Helsinki with formal approval from the
institutional review boards at each participating study site.
All subjects gave written informed consent. Recruitment
of patients with primary dystonia and neurologically
normal controls has been described (Xiao, et al. 2010;
LeDoux et al. 2012; Vemula et al. 2013). Demographics
and phenotypes for dystonia and control subjects are
presented in Table 1 and Table S1. The control subject
with trismus reported earlier (Xiao, et al. 2010) was
excluded from the analyses reported herein because of
uncertainty regarding how her phenotype should be classi-
fied. Of note, the data contained in Table 1 do not include
the family members of probands. In addition, all neurolog-
ically normal controls and all subjects classified as primary
dystonia were Caucasians of European descent. Minor
allele frequencies (MAFs) were compared with those
reported in 1000 Genomes (http://www.1000genomes.org)
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and Exome Variant Server (EVS) (http://evs.gs.washington.
edu) databases using Fisher’s exact test or Chi-square with
Yates correction.
HRM and genotyping
High-resolution melting (HRM) was performed with the
LightCycler 480 real-time polymerase chain reaction
(PCR) system and High Resolution Master Mix (Roche;
Indianapolis, IN) in accordance with manufacturer
instructions and our laboratory protocol (Xiao, et al.
2010). Melting curves and difference plots were analyzed
using Gene Scanning Software. For samples with shifted
melting curves, PCR products were cleaned using
ExoSAP-IT (United States Biochemical, Santa Clara,
CA) and sequenced in the forward and reverse directions
on an Applied Biosystems (Grand Island, NY) 3130XL
Genetic Analyzer (Table S2).
Extraction of RNA from leukocytes and
cell lines
Ambion’s (Grand Island, NY) LeukoLOCK™ Total RNA
Isolation System and TRI Reagent were used to isolate
RNA from peripheral blood leukocytes of subjects with
dystonia and controls. Using relative quantitative real-
time reverse transcription PCR (QRT-PCR), we examined
the effects of c.71+9C>A on THAP1 gene expression
in dystonia subjects harboring c.71+9C>A (n = 6) in
comparison to controls without the variant (n = 12). For
microarray, whole-genome gene expression studies, RNA
was extracted from lymphoblastoid cell lines derived from
six dystonia patients with c.71+9C>A and nine normal
controls without this variant. Sanger sequencing was used
to exclude coding, splice site, 5’ untranslated region, and
other previously reported intronic sequence variants (e.g.,
c.71+126T>C) from the controls.
To establish lymphoblastoid cell lines, peripheral blood
mononuclear cells were separated by centrifugation on a
sodium diatrizoate polysucrose gradient and transformed
with Epstein–Barr virus (Coriell, Camden, NJ). The lym-
phoblastoid cell lines were propagated in Roswell Park
Memorial Institute-1640 medium (Sigma-Aldrich, St.
Louis, MO) supplemented with 15% fetal bovine serum
(Sigma-Aldrich) and 2 mmol/L L-glutamine (Invitrogen,
Grand Island, NY) at 37°C in 5% CO2. Confluent cells
(1 9 106 cells/mL) were harvested for RNA using TRI
Reagent from Ambion. The quality of total RNA derived
from leukocytes and lymphoblastoid cell lines was
accessed with a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE) and Agilent
2100 Bioanalyzer using the Agilent RNA 6000 Nano Chip
kit. Subsequent downstream analyses were limited to sam-
ples with RNA Integrity Numbers greater than 8.0.
Relative quantitative reverse transcription
PCR
Reverse transcription was performed with Ambion’s
RETROscript™ kit using 500 ng of total RNA as template.
The reaction mixture was incubated at 44°C for 1 hr
followed by 10 min at 92°C. QRT-PCR was performed
Table 1. Clinical diagnoses and demographics.
Clinical diagnosis Number (age of onset)1 Family history2
Gender Number of subjects
with c.71+9C>AMale Female
Laryngeal dystonia 472 (45.4  15.7, 7–85) 8.3% 110 362 3
Cervical dystonia 509 (44.6  13.6, 4–76) 10.0% 118 391 3
Blepharospasm 198 (58.1  9.4, 20–73) 10.1% 61 137 2
Hand–forearm dystonia 52 (34.9  13.0, 7–60) 9.6% 23 29 0
Oromandibular dystonia 18 (52.5  12.3, 20–70) 11.1% 4 14 1
Other primary focal dystonia 38 (43.3  18.1, 10–74) 13.2% 15 23 0
Segmental dystonia 143 (48.0  12.2, 12–74) 12.6% 47 96 0
Multifocal dystonia 24 (33.3  16.1, 7–67) 20.8% 8 16 0
Generalized dystonia 26 (23.3  17.8, 1–57) 15.4% 12 14 0
Classified dystonias 1480 398 1082 9 (P = 0.0095)3
Unclassified dystonias4 192 NA NA NA 3
Dystonia total 1672 12 (P = 0.0035)3
Neurologically normal controls 1574 (61.2  14.4, 23–95) NA 688 886 1
NA, not available or applicable.
1Mean age at study enrollment  standard error, range (years).
2First- or second-degree relative with dystonia.
3Fisher’s exact test for case–control analysis.
4Subjects with unclassified dystonia were obtained from Athena Diagnostics.
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using the Roche LightCycler 480 with specific primers
for THAP1 and TOR1A (Table S2), along with Universal
ProbeLibrary (Roche) probes for human THAP1, TOR1A,
and the endogenous control (cyclophilin D). Four endoge-
nous controls (encoded proteins: cyclophilin D, b-tubulin,
TATA-binding protein, hypoxanthine-guanine phoshori-
bosyltransferase) were examined. Cyclophilin D showed the
smallest sample-to-sample variance. Student’s t-test was
used to compare RNA expression between dystonia and
control samples.
Whole-genome gene expression analysis
For microarray analyses, we used the Illumina Human-
HT-12 v.4 expression microarray platform (Illumina, San
Diego, CA) to assess the expression levels in each individ-
ual sample. These arrays investigate whole-genome
expression, providing coverage for more than 47,000
transcripts and known splice variants across the human
transcriptome. In total, 15 samples, six from patient
lymphoblastoid cell lines and nine from normal controls
were processed on two chips. Total RNA (200 ng) was
processed with the Illumina TotalPrep™ RNA Amplifica-
tion Kit (Applied Biosystems) to produce biotinylated
complementary RNAs (cRNAs). This procedure included
the reverse transcription of RNA to synthesize the first
strand complementary DNA (cDNA), second-strand
cDNA synthesis, cDNA purification, in vitro transcription
to synthesize cRNA, cRNA amplification, and purifica-
tion. The concentration of the cRNA solution was deter-
mined by measuring the absorbance at 260 nm/280 nm
using the NanoDrop 1000A spectrophotometer. The
biotinylated cRNAs (750 ng/sample) were hybridized to
the arrays for 20 h at 58°C. These direct hybridized
microarrays were scanned with the BeadArray reader
(Illumina, San Diego, CA). The raw data were processed
for errors and quality checks using Illumina’s proprietary
GenomeStudio software. Gene expression data were
quartile normalized and summarized further with Gene-
Spring GX 12.1 software (Agilent Technologies, Santa
Clara, CA). An unpaired t-test was done to filter probes
that were significant at P ≤ 0.05 with a mean fold change
≥1.5. Filtered probes were further investigated for biologi-
cal significance using WebGestalt Gene Set Analysis Tool-
kit 2.0 (http://bioinfo.vanderbilt.edu/webgestalt/) (Zhang
et al. 2005). The differentially expressed gene set was
compared to the human genome using the hypergeometric
test followed by correction for multiple testing using the
Benjamini and Hochberg (1995) (BH) method at a signifi-
cance level of 0.05 (False Discovery Rate < 0.05). Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways
were accessed from WebGestalt (Ashburner et al. 2000;
Kanehisa and Goto 2000). Dysregulated cellular networks
were examined with Ingenuity Pathway Analysis (IPA;
Ingenuity, Redwood City, CA).
Minigene assay and in silico analysis of
splicing
To test the effect of c.71+9C>A variant on splicing of
THAP1, we performed a minigene assay. The wild-type
minigene construct was produced by cloning into the
exon trap vector pET01 (MoBiTec, G€ottingen, Germany)
in two steps. First, we introduced genomic DNA encom-
passing ~400 bp 5′ to Exon 1, Exon 1, and ~400 bp of
Intron 1 into the pET01 vector. Genomic DNA was
amplified with the SequalPrep™ Long PCR Kit from Invi-
trogen, followed by digestion of the PCR product and
pET01 with XhoI and BamHI at 37°C for 2 h and then at
65°C for 20 min. This was followed by ligation of cohe-
sive-ended gel-purified digested PCR products into pET01
with the LigaFast™ Rapid DNA Ligation System from
Promega (Madison, WI). After sequence confirmation,
the second part of the gene, which included ~400 bp of
Intron 1, Exon 2, Intron 2, and ~600 bp of Exon 3, was
introduced into the minigene construct with BamHI and
NotI digestion (Table S3). After sequence confirmation,
the variant c.71+9C>A was introduced into the wild-type
minigene with the QuikChange II XL Site-Directed
Mutagenesis Kit from Stratagene (La Jolla, CA) to form
the mutant minigene.
Human embryonic kidney (HEK293) cells were trans-
fected in triplicates and total RNA was extracted
after 72 h with TRI Reagent. DNA was removed with
DNase I (Ambion) and total RNA quality was examined
with both agarose gel electrophoresis and a NanoDrop
ND-1000 spectrophotometer. Reverse transcription was
performed with Ambion’s RETROscript™ kit using
500 ng of total RNA as template. PCR products were
examined on a 1% agarose gel, followed by quantifying
the bands with ImageJ (http://rsbweb.nih.gov/ig/). Effects
of genotype were evaluated with a Student’s t-test.
The c.71+9C>A Intron 1 variant was further evaluated
for its effects on splicing using a broad array of in silico
programs which examine splicing, enhancer sites, and
silencer sites. The programs used included Relative
Enhancer and Silencer Classification by Unanimous
Enrichment exonic enhancer site (RESCUE-ESE) (Fair-
brother et al. 2002), Putative Exonic Splicing Enhancers/
Silencers (PESX) (Zhang and Chasin 2004), Human Splic-
ing Finder (HSF) (Desmet et al. 2009), NetGene2 (Brunak
et al. 1991), Splice Site Prediction by Neural Network
(NNSplice) (Reese et al. 1997), MaxEntScan (MES) (Yeo
and Burge 2004), ESEfinder (Cartegni et al. 2003),
and Automated Splice Site and Exon Definition Analyses
(ASSAED) (Rogan et al. 1998).
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Flow cytometry cell-cycle analysis
For flow cytometry, 10 9 106 lymphoblastoid cells were
washed with phosphate-buffered saline (PBS) and fixed
overnight with 90% ice-chilled ethanol at 20°C. Fixed
cells were then washed with 39 PBS followed by incuba-
tion with propidium iodide staining buffer (PBS with
RNaseA 100 lg/mL and propidium iodide 50 lg/mL) at
37°C for 30 min, and then overnight at 4°C in the dark.
The analysis was performed with a BD Biosciences LSR II
Flow Cytometer (San Jose, CA).
Results
Case–control analysis of THAP1 c.71+9C>A
frequency
The THAP1 c.71+9C>A variant (rs200209986) was found
in neurologically normal Caucasian controls with a MAF
of 0.0318% (1/3148). This is comparable to reports from
the 1000 Genomes project (MAF = 0.0916%, 2/2184) and
EVS database (MAF = 0.199%, 26/13006). In subjects
with dystonia, the MAF was significantly higher
(P < 0.05) at 0.359% (12/3344) when compared with the
1000 Genomes project and neurologically normal Cauca-
sian controls genotyped in this study. However, the differ-
ence in MAF did not reach statistical significance when
compared with the EVS database (P = 0.13).
Effects of c.71+9C>A on THAP1 and TOR1A
expression
In comparison to controls with no identified THAP1
sequence variants, leukocytes that harbored the
c.71+9C>A variant were associated with an elevated ratio
of Isoform 1 (NM_018105, 3-exon variant) to Isoform 2
(NM_199003, 2-exon variant) (Table 2). However, the
c.71+9C>A variant had no effect on overall expression of
THAP1. In addition, the c.71+9C>A variant had no effect
on expression of TOR1A in either lymphoblastoid cell
lines or leukocytes (Table S4).
THAP1 c.71+9C>A is associated with
transcriptional dysregulation
Microarray gene expression analysis revealed significant
upregulation of 234 genes; 277 genes were downregulated
(Tables S5, S6). Gene set enrichment analysis using
WebGestalt identified 29 significant KEGG pathways
(Table S7). Upregulated pathways included cytokine–
cytokine receptor interaction (LIF, IL4R, CCL5, TGFBR2,
LIFR, CCR2, and CXCL6), chemokine signaling (VAV3,
CCL5, PLCB2, CCR2, and CXCL6), natural killer
cell-mediated cytotoxicity (PPP3CA, VAV3, SH2D1A, and
RAET1E), WNT signaling (CTBP2, PPP3CA, PLCB2, and
WNT7A), phophatidylinositol signaling (PI4KA, DGKD,
and PLCB2), and JAK-STAT signaling (LIF, LIFR, IL4R,
and SOCS5). Downregulated pathways included MAPK
signaling (ELK4, FGFR3, RAC1, CACNG6, MAPK8IP2,
and PLA2G6), endocytosis (FGFR3, FOLR4, RNF41, and
ADRBK2), high-affinity receptor for the Fc region of
immunoglobulin E and vascular endothelial growth factor
(VEGF) signaling (RAC1, PLA2G2F, and PLA2G6) (Table
S8). IPA interactome analysis of upregulated genes identi-
fied CDKN1A, MDM2, and MYC as hubs (Fig. 1). ERK1/
2 was a major hub for downregulated genes (Fig. 2).
Top canonical pathways upregulated, as indicated by
IPA, included PI3K signaling. Top downregulated networks
were involved in L-3, 4-dihydroxyphenylalanine degrada-
tion, glutamine degradation, and 1,25-dihydroxyvitamin
D3 biosynthesis (Table S9).
c.71+9C>A alters THAP1 splicing
Minigene results from three wild-type and three c.71+9C>A
transfections showed that the c.71+9C>A variant exerted
significant effects on splicing patterns (P < 0.05) (Fig. 3).
Overall, mutant cells had reduced incorporation of Exon 2
and increased incorporation of Exon 3.
In silico analysis suggested that the c.71+9C>A variant
may exert deleterious effects on transcription of THAP1.
In aggregate, in silico analysis did not predict overt effects
on splicing although the c.71+9C>A variant did alter
enhancer locations. More specifically, HSF, NNSPLICE,
MES, NetGene2 predicted no changes in splicing due
to the mutant allele. On the other hand, ESEfinder,
RESCUE-ESE, PESX, and ASSAED indicated that ESEs
are altered by c.71+9C>A. RESCUE-ESE identified a new
site, whereas PESX showed the wild-type ESE site as
broken. ESEfinder indicated a drop in score from 93.79 to
90.90 for serine/arginine rich (SR) protein SC35. Other SR
proteins, splicing factor 2/alternative splicing factor (SF2/
ASF) and SRp40, were predicted to bind to new sites.
ASSAED incurred changes in SC35 (6.7 bits to 6.0 bits),
SRp40 (1.0 bits to 5.3 bits), SF2/ASF (from 0.4 bits to 2.1
bits). All programs reported that exonic silencer sites
(ESSs) remained unchanged by the c.71+9C>A variant.
THAP1 c.71+9C>A exerts effects on cell-cycle
control
Cell-cycle analysis of control and c.71+9C>A lymphoblas-
toid cell lines showed overt differences (Fig. 4). Mutant
variant cells, when compared with the normal wild-type
genotypes, showed an increased percentage of apoptosis
and decreased activity in G2 phase (Table S10).
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Discussion
Our study investigated the effects of a sequence variant
(c.71+9C>A, rs200209986) located within Intron 1 of
THAP1 on gene splicing and gene expression in subjects
with primary dystonia. The c.71+9C>A variant is rare
in Caucasian populations with a MAF at less than 0.1%
(1/3148) in our control cohort. This MAF is similar to
data from the 1000 Genomes but lower than the MAF
reported by the EVS database. In dystonia patients, the
MAF (c.71+9C>A) was significantly higher than the con-
trols of the 1000 Genomes project but not significantly
Table 2. THAP1 mRNA expression in wild-type and mutant cells.
Genotype/phenotype
Isoform 1 Isoform 2 Isoform 1/Isoform 2
Mean  SEM P1 Mean  SEM P1 Mean  SEM P1
Leukocytes
Normal controls (n = 12) 14.99  4.68 0.96 1.00  0.33 0.29 14.99  3.03 0.028
c.71+9C>A dystonia (n = 6) 14.93  5.10 0.70  0.27 21.25  3.90
Lymphoblastoid cell lines
Normal controls (n = 12) 10.14  0.41 0.19 1.06  0.05 0.24 9.63  0.30 0.99
c.71+9C>A dystonia (n = 6) 8.82  0.83 0.93  0.10 9.62  0.34
1P-value of t-test statistic.
Figure 1. Ingenuity interactome analysis of upregulated genes.
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higher than subjects in the EVS database. In other THAP1
screening series, this variant was reported in 3/455 sub-
jects with primary dystonia and 1/185 controls (Groen
et al. 2010), 1/567 dystonia subjects and 1/365 controls
(Lohmann et al. 2012), 0/109 dystonia subjects and 1/185
controls (Groen et al. 2011). In reports from other
groups, it is not entirely clear if population controls had
normal neurological examinations or a family history of
any movement disorder including dystonia. Moreover,
subjects recruited into EVS were not carefully examined
to exclude dystonia, the diagnosis of which can be
difficult even for an experienced general neurologist,
often requiring the expertise of a movement disorders
specialist. In addition, the EVS dataset is comprised of
2203 African-Americans and 4300 European-Americans,
whereas our cohort was limited to Caucasians. The EVS
cohort also included subjects with the extremes of spe-
cific traits and diseases including lipid disorders, hyper-
tension, and coronary artery disease. Finally, sequence
variants reported in the EVS dataset have not been vali-
dated with Sanger sequencing and some may be next-gen
read errors (LeDoux 2012c). Therefore, case–control com-
parisons using the EVS cohort as a “control” group is
problematic.
In vitro studies have identified a possible role for THAP1
in regulating the expression of TOR1A by binding to its
promoter region (Gavarini et al. 2010; Kaiser et al. 2010).
However, we did not detect an effect of variant THAP1 on
expression of TOR1A in either leukocytes or lymphoblas-
toid cell lines. Similarly, in previous work, RNAi knock-
down of THAP1 in fibroblasts showed no effect on
expression levels of TOR1A (Gavarini et al. 2010). Overex-
pression of THAP1 in ECs has been used as an indirect
means of identifying THAP1 targets – TOR1A was not
among the 16 genes that were significantly upregulated
or the 80 genes were downregulated (Cayrol et al. 2007).
Consistent with these results, THAP1 variants do not act as
disease modifiers in DYT1 dystonia (Kamm et al. 2011).
The effects of c.71+9C>A on THAP1 were studied with
an integrated collection of in silico and in vitro
approaches. Our in silico analysis showed that c.71+9C>A
exerted significant effects on the exon splicing enhancer
site, but not the splicing site. This finding is compatible
with recent work showing that intronic variants can exert
important effects on splicing enhancer sites (Fukao et al.
2010; Oeffner et al. 2011; Cohen et al. 2012; Jakubauski-
ene et al. 2012). Our in silico analysis was supported by a
minigene assay which showed significant alterations in
Figure 2. Ingenuity interactome analysis of downregulated genes.
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Figure 3. Minigene assay of THAP1 splicing. (A) Segments of THAP1 were cloned into the multiple cloning site (MCS) of the pET01 exon trap
vector, which contains a short stretch of a eukaryotic phosphatase gene (E) 3′ to the eukaryotic strong long terminal repeater promoter of the
Rous Sarcoma Virus (RSV). A second segment of E is followed by a polyadenylation site (pA). (B) The results of three wild-type and three
c.71+9C>A transfections showed that the C>A mutation exerted significant effects on splicing patterns in HEK293 cells (*P < 0.05, for all).
Figure 4. Cell-cycle analysis of lymphoblastoid cell lines. Data from representative normal and c.71+9C>A cells are shown. In comparison to
normal cells, the proportion of c.71+9C>A cells in apoptotic phase is increased and G2 phase is decreased.
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incorporation of Exons 2 and 3 in HEK293 cells transfect-
ed with the c.71+9C>A variant. In addition, leukocytes
harboring the c.71+9C>A variant showed an elevated
ratio of Isoform 1 (3-exon variant) to Isoform 2 (2-exon
variant). This could represent a false positive, however, as
we did not detect an effect of c.71+9C>A on splicing in
lymphoblastoid cell lines. Although not entirely concor-
dant, the minigene assay in HEK293 cells, in silico analy-
ses, and QRT-PCR results in lymphoblastoid cell lines
and leukocytes suggest that the c.71+9C>A variant may
exert deleterious effects on splicing in human brain. In
this regard, it is well-established that splicing shows tissue
type and developmental specificity (Heinzen et al. 2008;
Mondal et al. 2010).
Flow cytometry showed evidence of increased apoptosis
and cell-cycle disruption in the variant lymphoblastoid
cell lines. Previous studies defined a role for THAP1 as a
transcription factor binding to specific DNA sequences
and regulating cell proliferation through pRB/E2F cell-
cycle target genes (Clouaire et al. 2005; Cayrol et al.
2007). Furthermore, the pRB/E2F G1/S cell-cycle pathway
appears to play a central role in the pathogenesis of
dystonia, in general (LeDoux et al. 2013), and contributes
to the apoptotic dopaminergic cell death associated with
Parkinson’s disease (Hoglinger et al. 2007).
The limitations of our functional analysis are well-
recognized. Leukocytes and lymphoblastoid cell lines are
not ideal surrogates for neural tissues. In this regard,
the effects of genomic variants on splicing may be devel-
opmentally regulated and show tissue-type specificity.
Ideally, the relative roles of the major and minor THAP1
isoforms should be studied in a mammalian system via
transgenic expression of the respective cDNAs on a
THAP1-null background.
Gene expression data from lymphoblastoid cell lines
provided evidence of significant transcriptional dysregula-
tion associated with the c.71+9C>A variant. Upregulated
pathways included cytokine–cytokine receptor interaction,
chemokine signaling, cytotoxicity, Wnt signaling, and Jak-
STAT signaling. Two genes that play a central role in the
G1/S checkpoint pathway (CDKN1A and MDM2) were
hubs in the interactome for upregulated genes. Con-
versely, downregulated pathways included MAPK signal-
ing, endocytosis, and VEGF signaling. A critical element
of MAPK signaling (extracellular signal-regulated kinase
[ERK]1/2) was identified as a hub in the interactome for
downregulated genes.
The differentially expressed individual genes identified
in this study were mainly involved in cell division,
communication, migration, and survival. The mitotic cell
cycle is accomplished through a sequence of events that
include DNA replication (S phase) and mitosis (M phase),
separated by phases G1 and G2. This progression is
regulated by cyclin-dependent kinases (CDKs). Any
damage to the genome during these steps is corrected by
repair pathways or arrest of progression from one stage
to the next. Details from flow cytometry of c.71+9C>A
lymphoblastoid cells indicate that apoptosis occurred
prior to G1 with cells showing impairments in moving
through the G1/S checkpoint and, as a result, a smaller
percentage of cells were in the G2 phase. In a study by
Cayrol et al. (2007), the overexpression of THAP1 was
associated with inhibition of EC proliferation. Cell-cycle
analysis of ECs transfected with THAP1 siRNAs showed a
reduction in both the S-phase and G2/M-phase cell
populations and an increase in the number of cells in G1
thereby indicating the role of endogenous THAP1 in
G1/S cell-cycle progression (Cayrol et al. 2007). Their
data from both microarray and qPCR revealed that over-
expression of THAP1 in primary HUVECs (human
umbilical vein ECs) inhibits cell proliferation through
coordinated repression of critical cell-cycle regulators and
pRb/E2F target genes.
Upon phosphorylation, pRB is released, allowing the
E2F transcription factor to interact with the transcrip-
tional machinery of the cell, transcribing proteins crucial
for G1/S progression and the S phase of the cell cycle.
Phosphorylation of pRB is initiated by the cyclin D/Cdk4
and Cdk6 complex and continued by the cyclin E/Cdk2
complex. MAPK signaling, which was an enriched down-
regulated KEGG pathway in variant lymphoblastoid cells,
activates Cyclin D/Cdk4 and Cdk6.
The MAPK signaling family plays an important role in
complex cellular programs like proliferation, differentia-
tion, development, transformation, and apoptosis. At least
three MAPK pathways have been characterized: ERK, Jun
kinase (JNK/SAPK) and p38 MAPK (Zhang and Liu
2002). ERK, when activated, will translocate to nucleus and
change gene expression promoting differentiation or
mitosis. ERK1/2 is involved in activating the microtu-
bule-organizing center which controls the assembly of
cytosolic microtubules in interphase cells and the mito-
tic spindle of dividing cells (Verlhac et al. 1993). ERK
can translocate to the nucleus and phosphorylate tran-
scription factors including ELK1, ELK4, and Tal. The
ERK pathway can also link G0/G1 mitogenic signals to
the immediate early response. The ERK pathway is
known to be an intracellular checkpoint for cellular
mitogenesis. The ERK cascade is a key in controlling
the cell-cycle progression (Buchkovich and Ziff 1994).
The Raf-MEK-ERK cascade regulates the posttransla-
tional regulation of the assembly of cyclin D-Cdk4/6
complexes, which phosphorylate Rb protein causing
activation of the E2F transcription factors that regulate
the transcription of genes needed for G1/S transition
(Blanchard et al. 2000).
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Mean age of onset for THAP1-associated dystonia is
16.8 years and ranges from 3 to over 60 years (LeDoux
et al. 2012). Although DYT1 dystonia is widely viewed as
a neurodevelopmental circuit disorder (Xiao et al. 2004;
Zhao et al. 2011), neurodegenerative processes may
contribute to THAP1 and other mainly adult-onset dysto-
nias (LeDoux et al. 2013). In recent work, the c.71+9C>A
variant was associated with a significantly lower linear
density of Purkinje cells in postmortem cerebellum
from subjects with craniocervical dystonia and normal
controls (Prudente et al. 2013). Other findings in subjects
with craniocervical dystonia included ubiquitin-positive
Marinesco bodies in the substantia nigra and areas of focal
gliosis in cerebellar cortex. Transcriptional dysregulation in
lymphoblastoid cells lines from subjects harboring the
c.71+9C>A are compatible with these pathological findings
and current themes in dystonia research which point to
cerebellar Purkinje cells and nigrostriatal signaling as sites
of functional abnormalities.
In the context of relative neurodevelopmental and
neurodegenerative contributions to the pathogenesis of
mainly adult-onset primary dystonia, Wnt, Jak-STAT,
PI3K, and G1/S checkpoint pathways showed evidence of
dysregulation in c.71+9C>A cells. Wnt pathways contrib-
ute to cell polarity, transcriptional regulation, and intra-
cellular calcium homeostasis, all of which have been
implicated in dystonia (LeDoux 2011; LeDoux et al.
2013). The JAK-STAT system is a cell-surface to nucleus
signaling pathway leading to activation of genes that
contribute to cell growth and differentiation. PI3K
activates AKT which activates mammalian target of
rapamycin (mTOR). As such the PI3K pathway is often
referred to as the PI3K/AKT/mTOR pathway. The PI3K/
AKT/mTOR pathway is central to the biology of glial
tumors but also contributes to neural development
(Wong 2013).
Given the apparent histological changes associated with
c.71+9C>A postmortem human tissue and the results of
IPA interactome analyses, the G1/S checkpoint pathway is
a potential focal point of cellular pathology (Fig. 1).
CDKN1A directly interacts with the dystonia-associated
protein CIZ1 (Copeland et al. 2010). Moreover, other
dystonia-associated proteins including THAP1, TAF1,
ATM, and Ga(olf), contribute to the G1/S checkpoint
pathway (LeDoux et al. 2013). MDM2 is an E3 ubiquitin-
protein ligase and negative regulator of p53. In theory,
upregulation of CDKN1A and MDM2 could dampen
the effects of THAP1 loss-of-function variants on G1/S
cell-cycle control. Disturbances of the G1/S checkpoint
could manifest as ultrastructural neurodevelopmental
defects, apoptosis or both in terminally differentiated
neurons such as Purkinje cells (Florio et al. 2012; Jurk
et al. 2012).
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